PTCT vs. CORT, INDV, RYTM, MLTX, MOR, MRUS, DYN, ACAD, SMMT, and ARVN
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Corcept Therapeutics (CORT), Indivior (INDV), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), MorphoSys (MOR), Merus (MRUS), Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD), Summit Therapeutics (SMMT), and Arvinas (ARVN). These companies are all part of the "pharmaceutical preparations" industry.
PTC Therapeutics (NASDAQ:PTCT) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk.
PTC Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
In the previous week, PTC Therapeutics had 1 more articles in the media than Corcept Therapeutics. MarketBeat recorded 15 mentions for PTC Therapeutics and 14 mentions for Corcept Therapeutics. PTC Therapeutics' average media sentiment score of 0.96 beat Corcept Therapeutics' score of 0.54 indicating that PTC Therapeutics is being referred to more favorably in the media.
Corcept Therapeutics has a net margin of 21.86% compared to PTC Therapeutics' net margin of -62.45%. Corcept Therapeutics' return on equity of 21.98% beat PTC Therapeutics' return on equity.
Corcept Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics currently has a consensus price target of $33.67, indicating a potential downside of 0.01%. Corcept Therapeutics has a consensus price target of $40.10, indicating a potential upside of 60.02%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than PTC Therapeutics.
PTC Therapeutics received 16 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.58% of users gave Corcept Therapeutics an outperform vote while only 62.03% of users gave PTC Therapeutics an outperform vote.
93.6% of Corcept Therapeutics shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Corcept Therapeutics beats PTC Therapeutics on 13 of the 18 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
